Since the protein expression levels and/or regulation of NCX isoform/variants are disease related in many pathological states (e.g., heart failure, cardiac arrhythmia, and cerebral ischemia), the selective pharmacological targeting of tissue-specific NCX variants could be beneficial, although this remains challenging [16,17]. The gene discussed is TLX2; the disease is brain ischemia.